Skip to main content

Advertisement

SpringerLink
Log in

Preview of new drugs for overactive bladder and incontinence: Darifenacin, solifenacin, trospium, and duloxetine

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

This year, the US Food and Drug Administration will approve four new drugs indicated for the treatment of lower urinary tract dysfunction. Darifenacin, solifenacin, and trospium are antimuscarinic agents aimed at relieving the symptoms of overactive bladder and urge incontinence in men and women. Duloxetine will be the first drug approved for the treatment of female stress urinary incontinence. This article presents current data on the efficacy and tolerability of these new agents and invites the reader to decide whether they offer any potential advantages over existing therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rovner ES, Wein AJ: Incidence and prevalence of overactive bladder. Curr Urol Rep 2002, 3:434–438.

    Article  PubMed  Google Scholar 

  2. Luber KM: The definition, prevalence, and risk factors for stress urinary incontinence. Rev Urol 2004, 6(suppl 3):S3-S9.

    PubMed  Google Scholar 

  3. Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178.

    Article  PubMed  Google Scholar 

  4. Igawa Y: Discussion: functional role of M1,M2, and M3 muscarinic receptors in overactive bladder. Urology 2000, 55(suppl_5A):47–49.

    Article  PubMed  CAS  Google Scholar 

  5. Napier C, Gupta P: Darifenacin Is Selective for the Human Recombinant M3 Receptor Subtype. Heidelberg, Germany: ICS; 2002. http://contnet.org|url. Accessed May 4, 2004.

    Google Scholar 

  6. Miyamae K, Masaki Y, Murakami S, et al.: Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 2003, 69:205–211

    Article  PubMed  CAS  Google Scholar 

  7. Chapple CR, Yamanishi T, Chess-Williams R: Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002, 60:82–88.

    Article  PubMed  Google Scholar 

  8. Stevens L, Chess-Williams R, Chapple CR: Muscarinic receptor function in the idiopathic overactive bladder. J Urol 2004, 171(suppl 4):527a.

    Google Scholar 

  9. Eglen RM: Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci 2001, 68:2573–2578.

    Article  PubMed  CAS  Google Scholar 

  10. Watson GE, Culp DJ: Muscarinic cholinergic receptor subtypes in rat sublingual glands. Am J Physiol 1994, 266:C335-C342.

    PubMed  CAS  Google Scholar 

  11. Newgreen DT, Anderson DW, Carter AJ, et al.: Darifenacin: a novel bladder-selective agent for the treatment of urge incontinence. Neurourol Urodyn 1995, 14:555–557.

    Google Scholar 

  12. Moriya H, Takagi Y, Nakanishi T, et al.: Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci 1999, 64:2351–2358.

    Article  PubMed  CAS  Google Scholar 

  13. Hedge SS, Choppin A, Bonhaus D, et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997, 120:1409–1418.

    Article  Google Scholar 

  14. Scarpero HM, Dmochowski RR: Muscarinic receptors: what we know. Curr Urol Rep 2003, 4:421–428.

    Article  PubMed  Google Scholar 

  15. Braverman AS, Ruggieri MR, Pontari MA: The M2 muscarinic receptor subtype mediates cholinergic bladder contractions in patients with neurogenic bladder dysfunction. J Urol 2001, 165:36.

    Google Scholar 

  16. Tong YC, Chin WT, Cheng JT: Alterations in urinary bladder M2- muscarinic receptor protein and mRNA in 2-week streptozotocin-induced diabetic rats. Neurosci Lett 1997, 277:173–176.

    Article  Google Scholar 

  17. Pontari MA, Braverman AS, Ruggieri MR: The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol 2004, 286:R874-R880.

    PubMed  CAS  Google Scholar 

  18. Rovner ES, Wein AJ: Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep 2002, 4:385–390.

    Article  Google Scholar 

  19. Kerbusch T, Milligan PA, Karlsson MO: Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data. Br J Clin Pharmacol 2004, 57:170–180.

    Article  PubMed  CAS  Google Scholar 

  20. Rosario DJ, Cutinha PE, Chapple CR: The effects of single-dose darafenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur Urol 1996, 30:240.

    Google Scholar 

  21. Rosario DJ, Smith DJ, Radley SC, et al.: Pharmacodynamics of anticholinergic agents measured by ambulatory urodynamic monitoring: a study of methodology. Neurourol Urodyn 1999, 18:223–233.

    Article  PubMed  CAS  Google Scholar 

  22. Mundy AR, Abrams P, Chapple CR, Neal DE: Darifenacin, the First Selective M3 Antagonist for Overactive Bladder: Comparison with Oxybutynin on Ambulatory Urodynamic Monitoring and Salivary Flow. Seoul, Korea: ICS; 2001. http://contnet.org. Accessed May 4, 2004.

    Google Scholar 

  23. Chapple CR, Rechberger T, Al-Shukri S, et al.: Randomized, double-blind, placebo- and tolterodine-controlled trial of the once-daily anti-muscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004, 93:303–310. The first phase-3 study of an antimuscarinic agent to evaluate urgency as a primary efficacy variable in patients with OAB. Patients who received solifenacin experienced statistically significant reductions in daily urgency episodes relative to placebo.

    Article  PubMed  CAS  Google Scholar 

  24. Khullar V: Darafenacin, an M3 selective receptor antagonist, reduces the frequency of nocturnal awakening, an important symptom of overactive bladder [Abstract 491]. J Urol 2004, 171(suppl):131.

    Google Scholar 

  25. Haab F, Stewart L, Dwyer P: Darafenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004, 45:420–429.

    Article  PubMed  CAS  Google Scholar 

  26. Ikeda K, Kobyashi S, Miyata K, et al.: M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:97–103.

    Article  PubMed  CAS  Google Scholar 

  27. Kobayashi S, Ikeda K, Miyata K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004, 74:843–853.

    Article  PubMed  CAS  Google Scholar 

  28. Hatanaka T, Ukai M, Ohtake A, et al.: In vitro tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats and monkeys [Abstract 312]. Presented at the International Continence Society Meeting. Florence: October 5–9, 2003.

  29. Ohtake A, Hatanaka T, Ikeda K, et al.: In vivo bladder selective profile of solifenacin succinate (YM905) over salivary gland in mice and rats [Abstract 297]. Presented at the International Continence Society Meeting. Florence: October 5–9, 2003.

  30. Smulders RA, van Alphen W, Visser J, et al.: Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [Abstract 439]. Presented at the International Continence Society Meeting. Heidelberg, Germany: August 28–30, 2002.

  31. Chapple CR, Arano P, Bosch JH, et al.: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase-2 dose-finding study. BJU Int 2004, 93:71–77.

    Article  PubMed  CAS  Google Scholar 

  32. Chapple CR: Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase-3 studies [Abstract 487]. J Urol 2004, 171(suppl):130. Results of pooled data are presented from three large multicenter, double-blind, placebo-controlled studies assessing the efficacy, safety, and tolerability of darifenacin.

    Google Scholar 

  33. Gittelman M, Klimberg I, Fincer R, et al.: Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10mg YM905 versus placebo in male and female subjects with overactive bladder [Abstract DP43]. J Urol 2003, 169(suppl):349.

    Google Scholar 

  34. Kaufman J, Aurora CO, Knapp P: YM905 10mg increases the proportion of male and female patients with overactive bladder who become continent [Abstract DP49]. J Urol 2003, 169(suppl):351.

    Google Scholar 

  35. Hofner K, Oelke M, Machtens S, Grunewald V: Trospium chloride: an effective drug in the treatment of overactive bladder and detrusor hyper-reflexia. World J Urol 2001, 19:336–343.

    Article  PubMed  CAS  Google Scholar 

  36. Pak RW, Petrou SP, Staskin DR: Trospium chloride: A quaternary amine with unique pharmacologic properties. Curr Urol Rep 2003, 4:436–440. A comprehensive review on the unique properties of trospium chloride.

    Article  PubMed  Google Scholar 

  37. Fusgen I, Hauri D: Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther 2000, 38:223–234.

    PubMed  CAS  Google Scholar 

  38. Sand P, Dmochowski R: Trospium chloride improves symptoms of overactive bladder within one week [Abstract 370]. Presented at the 33rd Annual Congress of the International Continence Society. Florence, Italy: October 5–9, 2003.

  39. Cardozo L, Prescott K, Serdarevic D, Skillem L: Can medication prolong warning time? Presented at the 33rd Annual Congress of the International Continence Society. Florence, Italy: October 5–9, 2003. http://contnet.org

  40. Alloussi S, Laval KU, Eckert R, et al.: Trospium chloride in patients with motor urge syndrome: a double-blind, randomized, multicenter, placebo-controlled study. J Clin Res 1998, 1:439–451.

    Google Scholar 

  41. Stohrer M, Bauer P, Giannetti BM, et al.: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries: a multicenter, placebocontrolled, double-blind trial. Urol Int 1991, 47:138–143.

    Article  PubMed  CAS  Google Scholar 

  42. Madersbacher H, Stohrer M, Richter R, et al.: Trospium chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995, 75:452–456.

    PubMed  CAS  Google Scholar 

  43. Halaska M, Ralph G, Wiedemann A, et al.: Controlled, doubleblind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003, 20:392–399.

    PubMed  CAS  Google Scholar 

  44. Hofner K, Halaska M, Primus GL, et al.: Tolerability and efficacy of trospium chloride in a long-term treatment (52 weeks) in patients with urge syndrome: a double-blind, controlled, multicenter clinical trial. Neurourol Urodyn 2000, 19:487–488.

    Google Scholar 

  45. Zinner N, Gittelman M, Harris R, et al.: Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004, 171:2311–2315.

    Article  PubMed  CAS  Google Scholar 

  46. Todorova A, Vonderheid-Guth B, Dimpfel W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001, 41:636–644.

    Article  PubMed  CAS  Google Scholar 

  47. Espey MJ, Downie JW, Fine A: Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992, 221:167–170.

    Article  PubMed  CAS  Google Scholar 

  48. Gajewski J, Downie JW, Awad SA: Experimental evidence for a central nervous system site of action in the effect of alphaadrenergic blockers on the external urinary sphincter. J Urol 1984, 132:403–409.

    PubMed  CAS  Google Scholar 

  49. Rajaofetra N, Passagia JG, Marlier L, et al.: Serotoninergic, noradrenergic, and peptidergic innervation of Onuf’s nucleus of normal and transected spinal cords of baboons (Papio). J Comp Neurol 1992, 318:1–17.

    Article  PubMed  CAS  Google Scholar 

  50. Thor KB, Katofiase M: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neuronal control of lower urinary tract function in the chlorolose-anesthetized female cat. J Pharmacol Exp Ther 1995, 274:1014–1024.

    PubMed  CAS  Google Scholar 

  51. Sharma A, Goldberg MJ, Cerimele BJ: Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000, 40:161–167.

    Article  PubMed  CAS  Google Scholar 

  52. Lantz RJ, Gillespie TA, Rash TJ, et al.: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003, 31:1142–1150.

    Article  PubMed  CAS  Google Scholar 

  53. Norton PA, Zinner NR, Yalcin I, et al.: Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002, 187:40–48. The first placebo-controlled efficacy trial of duloxetine. Duloxetine resulted in statistically significant dose-dependent decreases in IEF with corresponding improvements observed in PGI-I and I-QOL scores.

    Article  PubMed  CAS  Google Scholar 

  54. Dmochowski RR, Miklos JR, Norton PA, et al.: Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 2003, 170:1259–1263.

    Article  PubMed  CAS  Google Scholar 

  55. Van Kerrebroeck P, Abrams P, Lange R, et al.: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 2004, 111:249–257.

    Article  CAS  Google Scholar 

  56. Millard RJ, Moore K, Renchen R, et al.: Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU Int 2004, 93:311–318.

    Article  PubMed  CAS  Google Scholar 

  57. Weston FL, Elser DM, Lawn O, et al.: Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence [Abstract]. AUA 2004, 1239.

  58. Raskin J, Goldstein DJ, Mallinckrodt CH, et al.: Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2004, 64:1237–1244.

    Article  Google Scholar 

  59. Schatzberg AF: Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry 2003, 64:30–37.

    Article  PubMed  CAS  Google Scholar 

  60. Diokno AC, Appell RA, Sand PK, et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003, 78:687–695.

    PubMed  CAS  Google Scholar 

  61. Appell RA, Sand P, Dmochowski R, et al.: Prospective, randomized, controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001, 76:359–363.

    Article  Google Scholar 

  62. Anderson RU, Mobley D, Blank B, et al.: Once daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809–1812.

    Article  PubMed  CAS  Google Scholar 

  63. Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine oncedaily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001, 57:414–421.

    Article  Google Scholar 

  64. Dmochowski RR, Davila GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580–586.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, University of Vermont School of Medicine, 1775 Williston Road, 05403, South Burlington, VT, USA

    Richard T. Kershen MD & Mike Hsieh BS

Authors
  1. Richard T. Kershen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mike Hsieh BS
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kershen, R.T., Hsieh, M. Preview of new drugs for overactive bladder and incontinence: Darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 5, 359–367 (2004). https://doi.org/10.1007/s11934-004-0083-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-004-0083-x

Keywords

Search

Navigation